Cover Image
市場調查報告書

中國的感染疾病治療市場:2016∼2020年

Infectious Disease Treatment Market in China 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 359323
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
Back to Top
中國的感染疾病治療市場:2016∼2020年 Infectious Disease Treatment Market in China 2016-2020
出版日期: 2016年05月26日 內容資訊: 英文 125 Pages
簡介

感染疾病是以細菌和寄生蟲、真菌、病毒等的病原性微生物為原因,從人到人直接、間接感染。為了除去感染源、阻止增生可使用抗感染劑。中國的感染疾病治療市場,預計2016∼2020年,以年複合成長率5.01%擴大。

本報告提供中國的感染疾病治療市場相關調查,市場現狀及2016∼2022年的市場成長預測,市場規模,加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 中國:概要

  • 社會經濟趨勢
  • 醫療改革
  • 醫療基礎設施

第6章 全球的供應商及國內供應商的機會

第7章 開發平台分析

第9章 各用途市場市場區隔

第10章 中國的抗菌劑市場

第11章 中國的抗病毒藥物市場

第12章 中國的抗真菌劑市場

第13章 中國的抗寄生蟲劑市場

第14章 市場趨勢

  • 氣象變動
  • 對科學物質及污染物質的暴露擴大
  • 聯合治療的使用
  • 感染疾病的罹患率上升
  • 意識的提高

第15章 促進要素的影響

第16章 市場課題

  • 假藥
  • 藥物抗性株的開發
  • 專利的失效與非專利進入
  • 研究的投資擴大
  • 學名藥及CAM的使用擴大

第16章 促進要素與課題的影響

第18章 市場趨勢

第19章 供應商環境

  • 競爭模式
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GSK
  • Johnson & Johnson
  • Merck
  • Pfizer
  • 其他值得注意的供應商

第20章 附錄

第21章 關於Technavio

圖表

目錄
Product Code: IRTNTR9389

About the Infectious Disease Treatment Market in China

Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic.

Technavio's analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

Technavio's report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GSK
  • Johnson & Johnson
  • Merck
  • Pfizer

Other Prominent Vendors

  • Achaogen
  • Actelion
  • Adenovir Pharma
  • AstraZeneca
  • Bayer
  • Biocryst
  • Celsus therapeutics
  • Cempra
  • Eleven Biotherapeutics
  • Exoxemis
  • Ferrer International
  • Griffin Discoveries
  • Hexima
  • InSite Vision
  • Insmed Incorporated
  • KaloBios Pharmaceuticals
  • Lytix Biopharma
  • Meiji Seika Pharma
  • Melinta Therapeutics
  • Moberg Pharma
  • NanoViricides
  • Nektar
  • NicOx
  • NovaBay
  • NovaBiotics
  • Ocular Therapeutix
  • Panoptes Pharma
  • Paratek Pharmaceuticals
  • Polichem
  • PTC Therapeutics
  • RedHill
  • Shire
  • Starpharma Holdings
  • Sun Pharma
  • Symbiomix
  • Tetraphase Pharmaceuticals
  • The Medicines Company
  • Theravance Biopharma
  • Topica Pharmaceuticals
  • Vertex Pharmaceuticals
  • Viamet Pharmaceuticals

Market driver

  • Use of combination therapies
  • For a full, detailed list, view our report

Market challenge

  • Development of drug resistant strains
  • For a full, detailed list, view our report

Market trend

  • Emergence of interferon (IFN)-free therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: China - An overview

  • Social and economic conditions
  • Healthcare reforms
  • Healthcare infrastructure

PART 06: Opportunities for global and local vendors

  • Local vendors
  • Global vendors

PART 07: Pipeline analysis

  • AC-170
  • DEXTENZA
  • Zerbaxa
  • Surotomycin
  • MK-3415A
  • Amikacin Inhale
  • CARBAVANCE
  • Eravacycline
  • Plazomicin
  • Delafloxacin
  • Solithromycin
  • VivaGel
  • Arikayce
  • Cadazolid
  • Ozenoxacin
  • TDT 067
  • MOB-015
  • 1334H
  • Auriclosene
  • EBI-005
  • FST-100
  • VT-1161
  • Luliconazole solution, 10%
  • ME1111
  • NP213
  • HXP124
  • SPL7013
  • OPX-1
  • AzaSite Xtra (ISV-405)
  • GD134
  • PART 08: Market landscape
  • Pharmaceutical market in China
  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by application

PART 10: Antibacterial drugs market in China

  • MOA
  • Market size and forecast

PART 11: Antiviral drugs market in China

  • Market size and forecast
  • Market segmentation by disease
  • Hepatitis C drugs market in China
  • Hepatitis B drugs market in China
  • HIV drugs market in China

PART 12: Antifungal drugs market in China

  • Market size and forecast

PART 13: Antiparasitic drugs market in China

PART 14: Market drivers

  • Climatic changes
  • Increased exposure to chemicals and pollutants
  • Use of combination therapies
  • Increased prevalence of infectious diseases
  • Increase in awareness

    PART 15: Impact of drivers

PART 16: Market challenges

  • Counterfeit drugs
  • Development of drug-resistant strains
  • Patent expiries and generic penetration
  • Decreased investments in research
  • Increased use of generics and CAMs

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Increase in collaborations and M&A
  • Emergence of IFN-free therapies
  • Increase in injection drug users

PART 19: Vendor landscape

  • Competitive scenario
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GSK
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: China GDP 2010-2014 ($ trillions)
  • Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP)
  • Exhibit 04: Healthcare reforms in China
  • Exhibit 05: New drug approval (NDA) review process in China
  • Exhibit 06: New drug approval process in China
  • Exhibit 07: Drug registration classification and requirements in China
  • Exhibit 08: Infectious diseases treatment market in China: Pipeline portfolio
  • Exhibit 09: Pharmaceutical market in China 2015-2020 ($ billions)
  • Exhibit 10: China pharmaceutical market overview: SWOT analysis
  • Exhibit 11: Share of infectious diseases market in pharmaceutical market in China 2015
  • Exhibit 12: Infectious disease treatment market in China 2015-2020 ($ billions)
  • Exhibit 13: Venues for purchasing anti-infective drugs in China
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Infectious disease treatment market in China segmentation by application
  • Exhibit 16: Infectious disease treatment market in China segmentation by application 2015
  • Exhibit 17: Infectious disease treatment market in China segmentation by application 2020
  • Exhibit 18: Infectious disease treatment market in China segmentation by application 2015-2020 ($ billions)
  • Exhibit 19: Infectious disease treatment market in China segmentation by application 2015-2020 (percentage)
  • Exhibit 20: Infectious disease treatment market in China 2015-2020
  • Exhibit 21: YoY growth rate of Infectious disease treatment market in China segments 2015-2020
  • Exhibit 22: MOA of antibacterial drugs
  • Exhibit 23: Antibacterial drugs market in China 2015-2020 ($ billions)
  • Exhibit 24: Segmentation of antibacterial drugs market by chemical class
  • Exhibit 25: Cephalosporin segmentation by generation of drugs
  • Exhibit 26: Antibacterial drugs market in China revenue segmentation by chemical class
  • Exhibit 27: Segmentation of antibacterial drugs market in China by drug origin
  • Exhibit 28: Antiviral drugs market in China 2015-2020 ($ billions)
  • Exhibit 29: Segmentation of antiviral drugs market in China by disease 2015
  • Exhibit 30: Segmentation of antiviral drugs market in China by disease 2020
  • Exhibit 31: Hepatitis C drugs market in China ($ billions)
  • Exhibit 32: Hepatitis B drugs market in China 2015-2020 ($ millions)
  • Exhibit 33: Segmentation of hepatitis B and C market based on MOA
  • Exhibit 34: HIV drugs market in China ($ millions)
  • Exhibit 35: HIV drugs market segmentation by drug class 2015
  • Exhibit 36: Antifungal drugs market in China 2015-2020 ($ millions)
  • Exhibit 37: Antifungal drugs market in China segmentation by chemical class
  • Exhibit 38: Antifungal drugs market segmentation by chemical class 2015
  • Exhibit 39: Antiparasitic drugs market in China ($ millions)
  • Exhibit 40: Impact of drivers
  • Exhibit 41: Antibiotic-resistant strains according to the period of development of resistance
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Pegasys (international) 2013-2015 ($ millions)
  • Exhibit 44: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Tamiflu (international) 2013-2015 ($ millions)
  • Exhibit 45: F. Hoffmann-La F. Hoffmann-La Roche: Key takeaways
  • Exhibit 46: Gilead Sciences: YoY revenue and growth rate of Truvada (international markets) 2013-2015 ($ millions)
  • Exhibit 47: Gilead Sciences: YoY revenue and growth rate of Atripla (international markets) 2013-2015 ($ millions)
  • Exhibit 48: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)
  • Exhibit 49: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)
  • Exhibit 50: Gilead Sciences: Key takeaways
  • Exhibit 51: GlaxoSmithKline: Key takeaways
  • Exhibit 52: Johnson & Johnson: YoY revenue and growth rate of Olysio (International markets) 2013-3015 ($ millions)
  • Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Prezista (international markets) 2013-3015 ($ millions)
  • Exhibit 54: Johnson & Johnson: YoY revenue and growth rate of Edurant (international markets) 2013-3015 ($ millions)
  • Exhibit 55: Johnson & Johnson: Key takeaways
  • Exhibit 56: Merck: YoY revenue and growth rate of Cancidas (international markets) 2013-2015 ($ millions)
  • Exhibit 57: Merck: YoY revenue and growth rate of Pegintron (international markets) 2013-2015 ($ millions)
  • Exhibit 58: Merck: YoY revenue and growth rate of Isentress (international markets) 2013-2015 ($ millions)
  • Exhibit 59: Merck: YoY revenue and growth rate of Invanz (international markets) 2013-2015 ($ millions)
  • Exhibit 60: Merck: YoY revenue and growth rate of Noxafil (international markets) 2013-2015 ($ millions)
  • Exhibit 61: Merck: YoY revenue of Cubicin (international markets) 2013-2015 ($ millions)
  • Exhibit 62: Merck: Key takeaways
  • Exhibit 63: Pfizer: YoY revenue and growth rate of Diflucan (emerging markets) 2013-2015 ($ millions)
  • Exhibit 64: Pfizer: YoY revenue and growth rate of Suplerazon (emerging markets) 2013-2015 ($ millions)
  • Exhibit 65: Pfizer: YoY revenue and growth rate of Tygacil (Emerging markets) 2013-2015 ($ millions)
  • Exhibit 66: Pfizer: YoY revenue and growth rate of Vfend (emerging markets) 2013-2015 ($ millions)
  • Exhibit 67: Pfizer: YoY revenue and growth rate of Zithromax (emerging markets) 2013-2015 ($ millions)
  • Exhibit 68: Pfizer: YoY revenue and growth rate of Zyvox (emerging markets) 2013-2015 ($ millions)
  • Exhibit 69: Pfizer: YoY revenue and growth rate of Tygacil (emerging markets) 2013-2015 ($ millions)
  • Exhibit 70: Pfizer: Key takeaways
Back to Top